EAU guidelines on prostate cancer

European Urology

Volumn 48, Issue 4, 2005, Pages 546-551

  Aus, G ^a   Abbou, C C ^b   Bolla, M ^c   Heidenreich, A ^d   Schmid, H P ^e   Van Poppel, H ^f   Wolff, J ^g   Zattoni, F ^h  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b HENRI MONDOR HOSPITAL   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g CARITAS KRANKENHAUS   (Germany)

^h SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Diagnosis; EAU guidelines; Follow up; Prostate cancer; Review; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOTOXIC AGENT; DOCETAXEL; HYDROCORTISONE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ANAMNESIS; BONE METASTASIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HEREDITY; HUMAN; INJECTION; LIFE EXPECTANCY; LOCAL ANESTHESIA; MASS SCREENING; MEDICAL LITERATURE; PAIN; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; TREATMENT INDICATION; TUMOR GROWTH; ULTRASOUND;

EID: 24644519463     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.06.001     Document Type: Article

References (12)

1. G. Aus, C.C. Abbou, D. Pacik, H.P. Schmid, H. van Poppel, and J.M. Wolff EAU guidelines on prostate cancer Eur Urol 40 2001 97 101
2. US Department of Health and Human services. Public Health Service, Agency for Health Care Policy and Research 1992. p. 115-27. http://www.ahcpr.gov/.
3. F. Bray, R. Sankila, J. Ferlay, and D.M. Parkin Estimates of cancer incidence and mortality in Europe in 1995 Eur J Cancer 38 2002 99 166
4. R.J. Black, F. Bray, J. Ferlay, and D.M. Parkin Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990 Eur J Cancer 33 1997 1075 1107
5. H. Gronberg, L. Damber, and J.E. Damber Familial prostate cancer in Sweden. A nationwide register cohort study Cancer 77 1996 138 143
6. B.S. Carter, T.H. Beaty, G.D. Steinberg, B. Childs, and P.C. Walsh Mendelian inheritance of familial prostate cancer Proc Natl Acad Sci USA 89 1992 3367 3371
7. N. Breslow, C.W. Chan, G. Dhom, Drury RAB, L.M. Franks, and B. Gellei Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France Int J Cancer 20 1977 680 688
8. L. Denis, M.S. Morton, and K. Griffiths Diet and its preventive role in prostatic disease Eur Urol 35 1999 377 387
9. L.H. Sobin C. Wittekind TNM Classification of Malignant Tumours 6th edn 2002 Wiley-Liss New York
10. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
11. H.J. De Koning, M.K. Liem, C.A. Baan, R. Boer, F.H. Schroder, and F.E. Alexander Prostate cancer mortality reduction by screening: power and time frame with complete enrolment in the European Randomized Screening for Prostate Cancer (ERSPC) trial Int J Cancer 98 2002 268 273
12. H.-P. Schmid, W. Riesen, and L. Prikler Update on screening for prostate cancer with prostate-specific antigen Crit Rev Oncol Hematol 50 2004 71 78